Antibodies and Fc-fusion antibody-like proteins have become successful biologics
developed for cancer treatment, passive immunity against infection, addiction, and …

Antibodies have been used for more than 100 years in the therapy of infectious diseases,
but a new generation of highly potent and/or broadly cross-reactive human monoclonal …

Background Whether a broadly neutralizing antibody (bnAb) can be used to prevent human
immunodeficiency virus type 1 (HIV-1) acquisition is unclear. Methods We enrolled at-risk …

The development of an effective AIDS vaccine has been challenging because of viral
genetic diversity and the difficulty of generating broadly neutralizing antibodies (bnAbs). We …

Adeno-associated viral vector-mediated transfer of DNA coding for broadly neutralizing anti-
HIV antibodies (bnAbs) offers an alternative to attempting to induce protection by vaccination …

Despite the success of potent anti-retroviral drugs in controlling human immunodeficiency
virus type 1 (HIV-1) infection, little progress has been made in generating an effective HIV-1 …

The identification of a new generation of potent broadly neutralizing HIV-1 antibodies
(bnAbs) has generated substantial interest in their potential use for the prevention and/or …

VRC01-class broadly neutralizing HIV-1 antibodies protect animals from experimental
infection and could contribute to an effective vaccine response. Their predicted germline …

Elicitation of broadly neutralizing antibodies (bnAbs) is a primary HIV vaccine goal. Native-
like trimers mimicking virion-associated spikes present nearly all bnAb epitopes and are …

Long-term delivery of anti-HIV monoclonal antibodies (mAbs) using adeno-associated virus
(AAV) vectors holds promise for the prevention and treatment of HIV infection. We describe a …